These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
662 related articles for article (PubMed ID: 28268222)
1. RASSF10 is Epigenetically Inactivated and Suppresses Cell Proliferation and Induces Cell Apoptosis by Activating the p53 Signalling Pathway in Papillary Thyroid Carcinoma Cancer. Fan C; Wang W; Jin J; Yu Z; Xin X Cell Physiol Biochem; 2017; 41(3):1229-1239. PubMed ID: 28268222 [TBL] [Abstract][Full Text] [Related]
2. microRNA-539 functions as a tumor suppressor in papillary thyroid carcinoma via the transforming growth factor β1/Smads signaling pathway by targeting secretory leukocyte protease inhibitor. Xu CB; Liu XS; Li JQ; Zhao X; Xin D; Yu D J Cell Biochem; 2019 Jun; 120(6):10830-10846. PubMed ID: 30706537 [TBL] [Abstract][Full Text] [Related]
3. LDOC1 inhibits proliferation and promotes apoptosis by repressing NF-κB activation in papillary thyroid carcinoma. Zhao S; Wang Q; Li Z; Ma X; Wu L; Ji H; Qin G J Exp Clin Cancer Res; 2015 Dec; 34():146. PubMed ID: 26637328 [TBL] [Abstract][Full Text] [Related]
4. RASSF10 suppresses colorectal cancer growth by activating P53 signaling and sensitizes colorectal cancer cell to docetaxel. Guo J; Yang Y; Yang Y; Linghu E; Zhan Q; Brock MV; Herman JG; Zhang B; Guo M Oncotarget; 2015 Feb; 6(6):4202-13. PubMed ID: 25638156 [TBL] [Abstract][Full Text] [Related]
5. Aberrant hypermethylation of the HOXD10 gene in papillary thyroid cancer with BRAFV600E mutation. Cao YM; Gu J; Zhang YS; Wei WJ; Qu N; Wen D; Liao T; Shi RL; Zhang L; Ji QH; Wang Y; Sun GH; Zhao YX; Wang YJ; Yu J; Zhu YX Oncol Rep; 2018 Jan; 39(1):338-348. PubMed ID: 29115628 [TBL] [Abstract][Full Text] [Related]
6. MicroRNA-96 plays an oncogenic role by targeting FOXO1 and regulating AKT/FOXO1/Bim pathway in papillary thyroid carcinoma cells. Song HM; Luo Y; Li DF; Wei CK; Hua KY; Song JL; Xu H; Maskey N; Fang L Int J Clin Exp Pathol; 2015; 8(9):9889-900. PubMed ID: 26617698 [TBL] [Abstract][Full Text] [Related]
7. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway. Ma Y; Qin H; Cui Y Biochem Biophys Res Commun; 2013 Nov; 441(4):958-63. PubMed ID: 24220341 [TBL] [Abstract][Full Text] [Related]
8. Epigenetic regulation of Wnt signaling pathway gene SRY-related HMG-box 17 in papillary thyroid carcinoma. Li JY; Han C; Zheng LL; Guo MZ Chin Med J (Engl); 2012 Oct; 125(19):3526-31. PubMed ID: 23044318 [TBL] [Abstract][Full Text] [Related]
9. Methylation of RASSF10 promotes cell proliferation and serves as a docetaxel resistant marker in human breast cancer. Dong T; Zhang M; Dong Y; Herman JG; van Engeland M; Zhong G; Guo M Discov Med; 2015 Nov; 20(111):261-71. PubMed ID: 26645898 [TBL] [Abstract][Full Text] [Related]
10. CHK2 Promotes Anoikis and is Associated with the Progression of Papillary Thyroid Cancer. Zhao W; Chen S; Hou X; Chen G; Zhao Y Cell Physiol Biochem; 2018; 45(4):1590-1602. PubMed ID: 29486482 [TBL] [Abstract][Full Text] [Related]
11. LncRNA SNHG12 promotes the proliferation and metastasis of papillary thyroid carcinoma cells through regulating wnt/β-catenin signaling pathway. Ding S; Qu W; Jiao Y; Zhang J; Zhang C; Dang S Cancer Biomark; 2018; 22(2):217-226. PubMed ID: 29630517 [TBL] [Abstract][Full Text] [Related]
12. LncRNA LINC00673 inhibits p53 expression by interacting with EZH2 and DNMT1 in papillary thyroid carcinoma. Meng XF; Zhao LY; Chu XF Eur Rev Med Pharmacol Sci; 2019 Mar; 23(5):2075-2083. PubMed ID: 30915752 [TBL] [Abstract][Full Text] [Related]
13. Expression of bcl-2, c-erbB-2, p53, and p21 (waf1-cip1) protein in thyroid carcinomas. Soda G; Antonaci A; Bosco D; Nardoni S; Melis M J Exp Clin Cancer Res; 1999 Sep; 18(3):363-7. PubMed ID: 10606183 [TBL] [Abstract][Full Text] [Related]
14. Patterns of expression of cell cycle/apoptosis genes along the spectrum of thyroid carcinoma progression. Saltman B; Singh B; Hedvat CV; Wreesmann VB; Ghossein R Surgery; 2006 Dec; 140(6):899-905; discussion 905-6. PubMed ID: 17188136 [TBL] [Abstract][Full Text] [Related]
15. Long noncoding RNA cancer susceptibility candidate 2 suppresses papillary thyroid carcinoma growth by inactivating the AKT/ERK1/2 signaling pathway. Huang F; Zhang Q; Chen W; Zhang H; Lu G; Chen J; Qiu C J Cell Biochem; 2019 Jun; 120(6):10380-10390. PubMed ID: 30609134 [TBL] [Abstract][Full Text] [Related]
16. RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma. Wang F; Feng Y; Li P; Wang K; Feng L; Liu YF; Huang H; Guo YB; Mao QS; Xue WJ Oncotarget; 2016 Jan; 7(4):4279-97. PubMed ID: 26701853 [TBL] [Abstract][Full Text] [Related]
17. miR-183 regulates biological behavior in papillary thyroid carcinoma by targeting the programmed cell death 4. Wei C; Song H; Sun X; Li D; Song J; Hua K; Fang L Oncol Rep; 2015 Jul; 34(1):211-20. PubMed ID: 26063221 [TBL] [Abstract][Full Text] [Related]
18. FoxM1 and its association with matrix metalloproteinases (MMP) signaling pathway in papillary thyroid carcinoma. Ahmed M; Uddin S; Hussain AR; Alyan A; Jehan Z; Al-Dayel F; Al-Nuaim A; Al-Sobhi S; Amin T; Bavi P; Al-Kuraya KS J Clin Endocrinol Metab; 2012 Jan; 97(1):E1-E13. PubMed ID: 22049175 [TBL] [Abstract][Full Text] [Related]
19. PIG3 plays an oncogenic role in papillary thyroid cancer by activating the PI3K/AKT/PTEN pathway. Xu J; Cai J; Jin X; Yang J; Shen Q; Ding X; Liang Y Oncol Rep; 2015 Sep; 34(3):1424-30. PubMed ID: 26133772 [TBL] [Abstract][Full Text] [Related]